Ingested (oral) IFN-α represses TNF-α mRNA in relapsing-remitting multiple sclerosis

被引：9

作者：

Brod, SA

Nguyen, M

Hood, Z

Shipley, GL

机构：

[1] Univ Texas, Hlth Sci Ctr, Dept Neurol, Houston, TX 77030 USA

[2] Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Quantitat Genom Core Lab, Houston, TX 77030 USA

来源：

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 2006年 / 26卷 / 03期

关键词：

D O I：

10.1089/jir.2006.26.150

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In a phase II trial in relapsing-remitting multiple sclerosis (RRMS), patients ingesting 10,000 IU, but not 30,000 IU, interferon-alpha (IFN-alpha) showed fewer gadolinium enhancements at months 5 and 6, along with decreased proinflammatory tumor necrosis factor-alpha (TNF-alpha) protein secretion. Therefore, we examined MxA mRNA induction and TNF-alpha mRNA repression after 100, 300, 1,000, 3,000, and 10,000 IU doses of ingested IFN-alpha in 24 RRMS patients to determine the optimal dose for future clinical trials in MS. Maximal TNF-alpha repression occurs at 100, 1,000, and 3,000 IU. These data provide new optimal doses for additional clinical studies using ingested IFN-alpha in MS.

引用

页码：150 / 155

页数：6

共 49 条

[1]

Aguet M, 1983, Interferon, V5, P1

[2] Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells [J].

Akerman, GS ;

Rosenzweig, BA ;

Domon, OE ;

McGarrity, LJ ;

Blankenship, LR ;

Tsai, CA ;

Culp, SJ ;

MacGregor, JT ;

Sistare, FD ;

Chen, JJ ;

Morris, SM .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2004, 549 (1-2) :43-64

[3] ANALYSIS OF T-REGULATOR CELL-SURFACE MARKERS AND FUNCTIONAL-PROPERTIES IN MULTIPLE-SCLEROSIS [J].

ANTEL, JP ;

PEEPLES, DM ;

REDER, AT ;

ARNASON, BGW .

JOURNAL OF NEUROIMMUNOLOGY, 1984, 6 (02) :93-103

[4] Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS [J].

Anthony, DC ;

Miller, KM ;

Fearn, S ;

Townsend, MJ ;

Opdenakker, G ;

Wells, GMA ;

Clements, JM ;

Chandler, S ;

Gearing, AJH ;

Perry, VH .

JOURNAL OF NEUROIMMUNOLOGY, 1998, 87 (1-2) :62-72

[5] TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study [J].

Arnason, BGW ;

Jacobs, G ;

Hanlon, M ;

Clay, BH ;

Noronha, ABC ;

Auty, A ;

Davis, B ;

Nath, A ;

Bouchard, JP ;

Belanger, C ;

Gosselin, F ;

Thibault, M ;

Duquette, P ;

Bourgoin, P ;

DuBois, R ;

Girard, M ;

Ebers, GC ;

Rice, GPA ;

Vandervoort, MK ;

Francis, GS ;

Duncan, L ;

Lapierre, Y ;

Freedman, MS ;

Christie, SN ;

Rabinovitch, HE ;

Patry, D ;

Murphy, WF ;

Peters, S ;

McGuiness, SD ;

Murray, TJ ;

Bhan, V ;

Maxner, CE ;

Van Dorpe, R ;

Oger, JJ ;

Nelson, J ;

Morrison, W ;

Bogle, N ;

Beall, S ;

Vorobeychick, G ;

Hiltbrunner, AV ;

Bock, J ;

Habil ;

Lesslauer, W ;

Li, DKB ;

Paty, DW ;

Zhao, GJ .

NEUROLOGY, 1999, 53 (03) :457-465

[6] INCREASED PRODUCTION OF INTERFERON GAMMA AND TUMOR NECROSIS FACTOR PRECEDES CLINICAL MANIFESTATION IN MULTIPLE-SCLEROSIS - DO CYTOKINES TRIGGER OFF EXACERBATIONS [J].

BECK, J ;

RONDOT, P ;

CATINOT, L ;

FALCOFF, E ;

KIRCHNER, H ;

WIETZERBIN, J .

ACTA NEUROLOGICA SCANDINAVICA, 1988, 78 (04) :318-323

[7] ABSORPTION OF CYTOKINES VIA OROPHARYNGEAL-ASSOCIATED LYMPHOID-TISSUES - DOES AN UNORTHODOX ROUTE IMPROVE THE THERAPEUTIC INDEX OF INTERFERON [J].

BOCCI, V .

CLINICAL PHARMACOKINETICS, 1991, 21 (06) :411-417

[8]

BOCCI V, 1990, J BIOL REG HOMEOS AG, V4, P81

[9]

BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13

[10]

BROD S, 2003, J NEUROL S2, V250, P140

← 1 2 3 4 5 →